On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Serena Williams has admitted she is using weight-loss drugs after struggling to shift her post-pregnancy weight. The 23-time Grand Slam tennis great said she has lost 31 pounds and wanted to speak out ...

Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and ...

Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval decision in 2023. In November 2024, the FDA also found quality control lapses ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

Terence Stamp, best known for his role playing the villain General Zod in the blockbuster films Superman and Superman II, has ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

Discover the top 11 websites to buy GLP-1 weight loss medications online. Our expert-reviewed guide helps you find safe and ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.